Search Results
May 13, 2026, 12:15 ET InventHelp Inventor Develops New Fish Suspending Device (PTA-608)
National sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 25-PTA-608, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission
More news about: InventHelp
May 07, 2026, 08:02 ET The Allstate Foundation commits $15M to increase youth-led service across the country
America, Future Business Leaders of America, Junior Achievement USA, National 4‑H Council, National Association of Secondary School Principals, National PTA and YMCA of the USA, with a combined reach of more than 30 million young people.NORTHBROOK, Ill.,
More news about: The Allstate Foundation
May 04, 2026, 09:02 ET National PTA Honors Students for Their Creativity in Reflections Art Program
Interpretation Award recipients are:Maurice IronheartSouth Canyon Elementary PTA, South DakotaDance Choreography: "Siyo Waci" Mika Chang Norman Rockwell PTA, Washington Film Production: "The Village of Balloons" Fernando Nunez El
More news about: National PTA
Apr 28, 2026, 20:52 ET CONCEPT MEDICAL STELLT VORLÄUFIGE 3-JAHRES-DATEN ZU SIRONA AUF DEM CHARING CROSS SYMPOSIUM 2026 VOR
Studie.In der aktuellen 3-Jahres-Analyse zeigte MagicTouch PTA, ein mit Sirolimus beschichteter Ballon, eine höhere Freiheit von klinisch bedingter Zielläsionsrevaskularisation (cdTLR) im Vergleich zur
More news about: Concept Medical
Apr 28, 2026, 09:24 ET CONCEPT MEDICAL 在「2026 年查令十字國際研討會」上公佈 SIRONA 的初步 3 年數據
Teichgräber 教授表示：「SIRONA 的初步 3 年數據令人振奮。 在如此長的跟進期內，使用 MagicTouch PTA 觀察到 cdTLR 持續減少，這令人非常鼓舞，也說明了基於西羅莫司的藥物輸送在股膕動脈介入治療中的持久性。 這些發現為該領域增添重要的長期隨機證據，並且在最終 CEC 審定前，這代表西羅莫司塗層球囊在周邊動脈疾病治療上具有非常光明的未來前景。 重要的是，這些發現不應被解讀為類別效應，而是強調需要基於可靠的臨床證據來評估各種西羅莫司塗層球囊技術。」Concept
More news about: Concept Medical
Apr 28, 2026, 06:41 ET CONCEPT MEDICAL ANUNCIA DADOS PRELIMINARES DE 3 ANOS DO SIRONA NO CHARING CROSS SYMPOSIUM 2026
ensaio.Na análise atual de 3 anos, o MagicTouch PTA, um balão revestido com sirolimo, mostrou maior liberdade de revascularização de lesão alvo clinicamente conduzida (cdTLR) em comparação com
More news about: Concept Medical
Apr 28, 2026, 06:32 ET CONCEPT MEDICAL ANUNCIA LOS DATOS PRELIMINARES A 3 AÑOS DE SIRONA EN EL SIMPOSIO CHARING CROSS 2026
ensayo.En el análisis actual de 3 años, MagicTouch PTA, un balón recubierto con sirolimus, mostró una mayor ausencia de revascularización de la lesión objetivo impulsada por motivos clínicos (cdTLR)
More news about: Concept Medical
Apr 28, 2026, 01:52 ET Concept Medical、チャリング・クロス・シンポジウム2026（Charing Cross Symposium 2026）でSIRONAの3年予備データを発表
Teichgräber教授は、次のように述べています。「SIRONAの3年予備データは非常に期待を抱かせるものです。MagicTouch PTA によるcdTLRの持続的な低下を、このような長期追跡期間を通じて確認できたことは非常に心強く、大腿膝窩動脈インターベンションにおけるシロリムスベースの薬物送達の持続性を示しています。これらの知見は、この分野に重要な長期無作為化エビデンスを加えるものであり、CECによる最終判定を待つ段階ではあ
More news about: Concept Medical
Apr 27, 2026, 22:56 ET CONCEPT MEDICAL ANNONCE LES DONNÉES PRÉLIMINAIRES À 3 ANS DE SIRONA AU SYMPOSIUM CHARING CROSS 2026
sécurité.Dans l'analyse actuelle à 3 ans, MagicTouch PTA, un ballonnet enrobé de sirolimus, a révélé une plus forte absence de revascularisation de la lésion cible d'origine clinique (cdTLR) par
More news about: Concept Medical
Apr 27, 2026, 22:48 ET Concept Medical anuncia datos preliminares de 3 años sobre Sirona en el Simposio de Charing Cross 2026
ensayo.En el análisis actual de 3 años, MagicTouch PTA, un balón recubierto de sirolimus, mostró una mayor ausencia de revascularización de la lesión diana clínicamente indicada (cdTLR) en comparación
More news about: Concept Medical
Apr 27, 2026, 21:00 ET Cordis 社、SELUTION SLR™ PTA薬剤溶出バルーン（DEB）を日本で販売開始
グローバルな展開と深いオペレーションの専門性に支えられています。臨床アウトカムの向上、顧客中心のサービス、そして価値ある教育の提供に注力し、Cordis 社は心血管治療の変革という使命の実現に向けて取り組んでいます。 販売名： SELUTION SLR PTA 薬剤溶出バルーンカテーテル 医療機器承認番号：30700BZI00031000Soga, Y. et al. 3-Year Results Following Femoropopliteal Lesion Treatment With a Novel Sirolimus-Eluting
More news about: Cordis
Apr 27, 2026, 06:43 ET CONCEPT MEDICAL ANNOUNCES PRELIMINARY 3-YEAR SIRONA DATA AT CHARING CROSS SYMPOSIUM 2026
endpoints.In the current 3-year analysis, MagicTouch PTA, a sirolimus-coated balloon, showed higher freedom from clinically driven target lesion revascularization (cdTLR) compared with the paclitaxel-coated
More news about: Concept Medical
Apr 27, 2026, 06:38 ET CONCEPT MEDICAL ANNOUNCES PRELIMINARY 3-YEAR SIRONA DATA AT CHARING CROSS SYMPOSIUM 2026
endpoints.In the current 3-year analysis, MagicTouch PTA, a sirolimus-coated balloon, showed higher freedom from clinically driven target lesion revascularization (cdTLR) compared with the paclitaxel-coated
More news about: Concept Medical
Apr 23, 2026, 11:00 ET FLEX Vascular Announces 12-Month Real-World Outcomes Demonstrating Strong Safety, Durability, and Reduced Reinterventions with FLEX™ Vessel Prep System
cephalic arch lesions, nearly doubling historical PTA benchmarks100% secondary patency in AV grafts at 12 months, with no access abandonmentResulting in the elimination of 1 intervention per patient per year (on average) when FLEX is used with PTA."These results suggest a meaningful
More news about: FLEX Vascular
Apr 23, 2026, 11:00 ET FLEX Vascular Announces 12-Month Real-World Outcomes Demonstrating Strong Safety, Durability, and Reduced Reinterventions with FLEX™ Vessel Prep System
cephalic arch lesions, nearly doubling historical PTA benchmarks100% secondary patency in AV grafts at 12 months, with no access abandonmentResulting in the elimination of 1 intervention per patient per year (on average) when FLEX is used with PTA."These results suggest a meaningful
More news about: FLEX Vascular
Apr 23, 2026, 11:00 ET FLEX Vascular gibt 12-Monats-Ergebnisse aus der Praxis bekannt, die eine hohe Sicherheit, Langlebigkeit und weniger Reinterventionen mit dem FLEX™ Vessel Prep System belegen
hoch wie die bisherigen PTA-Benchmarks100 % sekundäre Durchgängigkeit bei AV-Transplantaten nach 12 Monaten, ohne dass der Zugang aufgegeben wurdeDas bedeutet, dass im Durchschnitt 1 Eingriff pro Patient und Jahr vermieden werden kann, wenn FLEX zusammen mit PTA eingesetzt wird."Diese
More news about: FLEX Vascular
Apr 23, 2026, 11:00 ET FLEX Vascular annonce des résultats en situation réelle sur 12 mois démontrant une sécurité et une durabilité élevées ainsi qu'une réduction des réinterventions avec le système FLEX™ Vessel Prep.
historiques en matière d'ATP.100 % de perméabilité secondaire des greffons AV à 12 mois, sans abandon d'accèsL'utilisation du FLEX avec la PTA permet d'éliminer une intervention par patient et par an (en moyenne)."Dans une population réelle, nous constatons une grande sécurité,
More news about: FLEX Vascular
Apr 08, 2026, 12:30 ET InventHelp Inventor Develops Comfortable Towel Covering (PTA-601)
National sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 25-PTA-601, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission
More news about: InventHelp
Apr 08, 2026, 12:00 ET InventHelp Inventor Develops New Walk Gate Closer (PTA-600)
Portland sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 25-PTA-600, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission
More news about: InventHelp
Apr 08, 2026, 11:45 ET InventHelp Inventor Develops New Cleaning Tool for Pickup Trucks (PTA-489)
Portland sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 25-PTA-489, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission
More news about: InventHelp
Apr 08, 2026, 11:30 ET InventHelp Inventor Develops New Dispensing Device for Marking Paint (PTA-473)
Portland sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 25-PTA-473, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission
More news about: InventHelp
Apr 06, 2026, 14:59 ET BayPort Credit Union Celebrates Financial Literacy Month with Workshops, Prizes, and Community Programs
$1 each month for three consecutive months into a BayPort Savings account, participants can win $1,000 for themselves and $1,000 for their school's PTA—while learning about the importance of maintaining a savings fund.
More news about: BayPort Credit Union
Apr 05, 2026, 23:28 ET SirPAD：PADにおけるシロリムスコーティングバルーンの安全性と有効性を確認する主要結果
Medicineにも同時に掲載されました。SirPAD試験では、大腿膝窩動脈または膝下のPAD患者1,252人が登録され、シロリムスコーティングバルーンMagicTouch PTA または非コーティングバルーンのいずれかによる血管形成術を受ける群に無作為に割り付けられました。主要アウトカムである主要下肢有害事象（MALE）は、標的肢に対する大規模な予定外切断または重症虚血に対する標的病変血行再建を含み、1年後の発生率はシロリムスコーティングバルーン群で8.8％、非コーティングバルーン群で15％であり、リスク差の中央値の偏り補正推定値は-4.9％でした。この差は、MagicTouch
More news about: Concept Medical
Apr 05, 2026, 23:23 ET SirPAD: Primäre Ergebnisse bestätigen die Sicherheit und Wirksamkeit des mit Sirolimus beschichteten Ballons bei peripherer arterieller Verschlusskrankheit (Peripheral Arterial Disease, PAD)
entweder mit dem sirolimusbeschichteten Ballon MagicTouch PTA oder einer Angioplastie mit einem unbeschichteten Ballon behandelt wurden. Das primäre Ergebnis schwerwiegender unerwünschter Ereignisse an den Extremitäten
More news about: Concept Medical
Apr 05, 2026, 23:18 ET SirPAD : les principaux résultats confirment l'innocuité et l'efficacité du ballon enrobé de sirolimus dans le traitement de la maladie artérielle périphérique (MAP)
recevoir soit le ballonnet enrobé de sirolimus MagicTouch PTA, soit une angioplastie par ballonnet non enrobé. Le résultat principal, à savoir les événements indésirables majeurs du membre (MALE), comprenant les
More news about: Concept Medical